-$0.12 EPS Expected for Rockwell Medical Inc (NASDAQ:RMTI) This Quarter

Equities research analysts expect Rockwell Medical Inc (NASDAQ:RMTI) to report earnings of ($0.12) per share for the current quarter, according to Zacks. Two analysts have made estimates for Rockwell Medical’s earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.11). Rockwell Medical posted earnings per share of ($0.15) during the same quarter last year, which indicates a positive year-over-year growth rate of 20%. The business is expected to issue its next quarterly earnings results on Thursday, March 12th.

On average, analysts expect that Rockwell Medical will report full-year earnings of ($0.57) per share for the current year, with EPS estimates ranging from ($0.59) to ($0.56). For the next financial year, analysts expect that the company will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.44) to ($0.20). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Rockwell Medical.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings results on Monday, November 11th. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. Rockwell Medical had a negative net margin of 57.77% and a negative return on equity of 139.38%. The business had revenue of $15.41 million for the quarter, compared to analyst estimates of $15.40 million.

A number of research firms have issued reports on RMTI. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Rockwell Medical in a report on Monday. Piper Jaffray Companies cut their price objective on shares of Rockwell Medical from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Finally, Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $9.33.

RMTI traded down $0.06 on Wednesday, reaching $2.09. The company had a trading volume of 235,800 shares, compared to its average volume of 345,819. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.98 and a current ratio of 3.27. The stock has a market cap of $134.64 million, a P/E ratio of -4.45 and a beta of 1.45. Rockwell Medical has a fifty-two week low of $1.81 and a fifty-two week high of $6.88. The company’s fifty day moving average is $2.23 and its 200 day moving average is $2.94.

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP bought a new stake in shares of Rockwell Medical during the 1st quarter worth approximately $57,000. Dillon & Associates Inc. bought a new position in Rockwell Medical in the 3rd quarter valued at approximately $34,000. Greenleaf Trust bought a new position in Rockwell Medical in the 2nd quarter valued at approximately $36,000. Royal Bank of Canada lifted its stake in Rockwell Medical by 61.7% in the 2nd quarter. Royal Bank of Canada now owns 12,125 shares of the company’s stock valued at $37,000 after purchasing an additional 4,625 shares during the last quarter. Finally, Gabelli Funds LLC bought a new position in Rockwell Medical in the 2nd quarter valued at approximately $49,000. 21.41% of the stock is owned by institutional investors.

About Rockwell Medical

Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.

See Also: What is a CD ladder?

Get a free copy of the Zacks research report on Rockwell Medical (RMTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.